Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy

Pei-Wei Huang1 | Ching-Fu Chang1 | Chia-Yen Hung1,2 | Shun-Wen Hsueh3 | Pei-Hung Chang3 | Kun-Yun Yeh3 | Jen-Shi Chen1 | Yen-Yang Chen4 | Chang-Hsien Lu5 | Yu-Shin Hung1 | Wen-Chi Chou1

1Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
2Division of Hematology-Oncology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
3Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan
4Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan
5Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi, Taiwan

Correspondence
Wen-Chi Chou, Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, #5, Fu-Hsing Street, Kwei-Shan District, Taoyuan, Taiwan.
Email: wenchi3992@yahoo.com.tw

Funding information
This research was not funded by any public, commercial, or nonprofit agency.

Abstract

Background: We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S-1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen.

Patients and methods: We retrospectively analyzed 727 APC patients who received first-line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in-group survival differences with monotherapy or combination therapy.

Results: The median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI], 1.22-1.88, P < .001) and 2.84 (95% CI, 2.34-3.45, P < .001). The best tumor responses with either partial response or stable disease were 57.5%, 40.4%, and 17.2% of patients in the good, intermediate, and poor prognostic groups (P < .001), respectively. For patients in the good prognostic group, first-line chemotherapy with monotherapy and combination therapy had similar median survival times (13.8 vs 12.9 months, P = .26), while combination therapy showed a better median survival time than monotherapy in patients in the intermediate and poor prognostic groups (8.5 vs 8.0 months, P = .038 and 5.7 vs 3.7 months, P = .001, respectively).

Conclusion: The results of our study supported the application of the GS model as a general prognostic tool for patients with pancreatic cancer receiving first-line palliative chemotherapy with gemcitabine-based regimens.

KEYWORDS
palliative chemotherapy, pancreatic cancer, prognostic model
1 | INTRODUCTION

Pancreatic cancer is one of the most lethal cancers worldwide; as more than 80% of patients present with unresectable disease at diagnosis,1,2 palliative chemotherapy is the standard of care.3 Gemcitabine has been the backbone of chemotherapy for advanced pancreatic cancer (APC) for several decades with clinical benefits of prolonging survival time and ameliorating patient quality of life 4; however, gemcitabine monotherapy has demonstrated a tumor response rate of 6%-11% and a median survival time of 5.6-8.8 months in APC.4,6 Recent clinical studies using combination regimens including 5-flourouracil (5-FU) plus folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel have shown improved survival outcomes compared to those of gemcitabine monotherapy.5,6 Even though patients received high-intensity treatment, the median survival times were around 11.1 months in patients treated with FOLFIRINOX and 8.5 months in patients treated with gemcitabine plus nab-paclitaxel.5,6 Unfortunately, these high-intensity treatments are inevitably associated with higher treatment-related toxicity.7,8 For example, grade 3 or 4 neutropenia occurred in 45% of patients treated with FOLFIRINOX and 38% of patients treated with gemcitabine plus nab-paclitaxel.5,6 Due to the marginal survival benefits and increased toxicity profiles, early meta-analysis studies suggested that combination therapies should be reserved for APC patients with good performance status.7-10

While palliative chemotherapy has shown prolonged survival,4-6 there is an essential need to identify APC patients who might benefit the most and the least from such treatment since chemotherapy is often accompanied by extreme toxicity.4-10 We previously developed a robust prognostic model (the GS model) 11 to predict survival outcomes of APC patients who received first-line palliative chemotherapy with gemcitabine plus S-1 (GS regimen).12 Four independent variables—performance status, tumor stage, albumin, and neutrophil-to-lymphocyte ratio (NLR)—were selected to construct the model, which categorized patients into different prognostic groups for survival prediction. The clinical variables of the GS model are easily accessed upon antitumor therapy; therefore, we believed that this model might be applicable to patients with APC receiving all chemotherapeutic regimens. The GS prognostic model was originally designed to predict survival outcome in APC patients who received first-line palliative chemotherapy with GS regimen. The primary outcome of this study aimed to validate the performance and validate the application of the GS model to APC patients receiving first-line palliative chemotherapy regimens other than GS.

2 | MATERIALS AND METHODS

2.1 | Patient selection

We constructed a retrospective medical chart review to select consecutive patients who underwent first-line palliative chemotherapy for unresectable or metastatic pancreatic cancer (APC) between 2010 and 2016 at four institutions in Taiwan. Patients who had recurrent tumor after receiving adjuvant chemotherapy, experienced a concurrent active malignancy, received GS regimen or concomitant radiotherapy during first-line palliative chemotherapy were excluded. A total of 727 patients who received palliative chemotherapy other than the GS regimen as the first-line treatment were included in this study. The choice of chemotherapy regimens was determined by the primary care physician on the basis of the patients and physicians’ preference. S-1 is an oral 5-FU derivative and has been widely used in Asian countries for treating pancreatic cancer according to Gemcitabine and S-1 Trial (GEST) study.12 S-1 monotherapy was provided at a dose of 80-120 mg daily on day 1 to day 14 every 21 days or on day 1 to day 28 every 42 days.12 This study was approved by the institutional review boards and was conducted in compliance with the principles of the Declaration of Helsinki (1996). The requirement of informed consent from participants was waived by the Institutional Review Board because no protected health information was included in this retrospective study.

2.2 | Data collection and follow-up

Patient demographic data were recorded by primary care physicians using a prospectively formulated electronic data form described in detail elsewhere.8 All biochemistry laboratory data were obtained within 7 days prior to chemotherapy initiation. Monotherapy and combination therapy were respectively defined as the administration of one and more than one kind of chemotherapeutic agent. Tumor response was evaluated using computed tomography (CT) scan according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.13 Image studies were performed and interpreted by an institutional radiologist at baseline and were repeated every 12 weeks (the exact interval was at the physician’s discretion) to evaluate tumor response. Overall survival (OS) was calculated from the time of chemotherapy initiation until the date of death from any cause. All included patients were followed-up until death or 31 December 2017. All dates of death were obtained from either the Institutional Cancer Registry or the National Registry of Death database in Taiwan.

2.3 | Statistical analysis

Basic demographic data were summarized as n (%) for categorical variables and as medians with 95% confidence
intervals (CIs) for continuous variables. Four predefined variables—tumor stage, performance status, albumin, and NLR—selected from the GS model, were evaluated using univariate Cox regression to assess the impact of each variable on patient OS. All four variables were further analyzed using a multivariate Cox proportional hazards model with backward selection.

The prognostic score was calculated for each patient using the GS model, as shown below:

*Prognostic score* = 3 + (0 for ECOG PS 0 or 1; 0.359 for ECOG PS 2; 2.709 for ECOG PS 3) + (0 for stage III; 1.636 for stage IV) + 0.186 × NLR (100%) − 0.547 × albumin (gm/dL)

The patients were categorized into good (prognostic score <2.7), intermediate (prognostic score 2.7-3.3), and poor prognostic groups (prognostic score >3.3) according to the GS model. Survival time was analyzed using the Kaplan-Meier method. Log-rank tests were used to determine significant differences among the survival curves. The C-index was calculated to assess the performance of the GS model. The C-index is a generalization of the area under the receiver operating characteristic curve, which measures the discrimination of model. The value of C-index ranges from 0.5 (no discrimination) to 1.0 (perfect discrimination). All statistical assessments with *P* < .05 were considered significant.

3 | RESULTS

3.1 | Patient characteristic

Comparisons of the distributions of patient characteristics in the study cohort (non-GS cohort) and the cohort used in the development of the GS model (GS cohort) are shown in Table 1. In the non-GS cohort, the median age was 63 years (range, 23-89) and 431 patients (59.3%) were men. In this cohort, 565 patients (77.7%) had metastatic disease with the liver as the most common metastatic site (52.4%), followed by the peritoneum (28.6%) and distant lymph nodes (18.3%). The most common chemotherapy regimen used for first-line treatment was gemcitabine-based combination therapy (50.6%), followed by gemcitabine alone (36.3%), 5-FU or S-1 alone (9.5%), and combination therapy with miscellaneous agents (3.6%). Less than 1% of non-GS cohort patients had been treated with gemcitabine + Nab-paclitaxel or FOLFIRINOX regimen because of a lack of insurance support. Compared to the demographic data of patients in the GS cohort, patients in the non-GS cohort were characterized by higher proportions of nonsmoking patients and those with primary tumors located at the pancreatic head.

3.2 | Survival outcome and performance of the GS model

The median OS time was 7.4 months (95% CI, 7.0-7.9) and 57 (7.8%) patients remained alive at the end of the study. Table 2 shows the results of univariate and multivariate analyses of the variables within the GS model for OS. All four variables, (ECOG performance, tumor stage, albumin level, and NLR) were significant prognostic factors for OS in both univariate and multivariate analysis.

Figure 1 shows the linear correlation between the GS model scores and survival times (R² = 0.116). Patients with a lower prognostic score had a longer survival time. The C-index of the GS model applied to the non-GS cohort was 0.73 (95% CI, 0.70-0.77).

Based on the GS model, 32.4%, 29.7%, and 37.8% of the patients were assigned to the good, intermediate, and poor prognostic groups, respectively. The median survival times for these three groups were 13.4 (95% CI, 11.8-15.0), 8.4 (95% CI, 7.7-9.0), and 4.6 (95% CI, 4.1-5.1) months, respectively. Kaplan-Meier survival curves of patients from different prognostic groups are shown in Figure 2. The hazard ratios for the comparison of the intermediate and poor prognostic groups to the good prognostic group were 1.51 (95% CI, 1.22-1.88, *P* < .001), and 2.84 (95% CI, 2.34-3.45, *P* < .001), respectively (Table 3). The performance of the GS model among patients receiving different chemotherapy regimens is shown in Table 3. Overall, the OS was distinctly longer in the good prognostic group than that in the poor prognostic group across different chemotherapeutic regimens (Figure S1).

Of the non-GS cohort, first-line chemotherapy showed the best treatment response of partial response (PR) in 62 (8.5%) patients, stable disease (SD) in 183 (25.2%) patients, and progressive disease (PD) in the remaining 482 (66.3%) patients. The best treatment responses of PR, SD, and PD occurred in 12.9%, 44.6%, and 42.5% of patients in the good prognostic group; 8.3%, 32.1%, and 59.6% of patients in the intermediate prognostic group; and 6.3%, 10.9%, and 82.8% of patients in the poor prognostic group, respectively (chi-square test *P* < .001, Figure 3).

3.3 | Impact of monotherapy or combination therapy among prognostic groups

To evaluate the impact of chemotherapy regimen on survival outcome among the different prognostic groups, all patients were categorized as having received either monotherapy or combination therapy as the first-line treatment for pancreatic cancer. In the good prognostic group, the median OS were 13.8 (95% CI, 11.6-16.0 months) and 12.9 (95% CI, 10.5-15.3 months, *P* = .26) months for patients
| Characteristic                  | Non-GS cohort (n = 727), N (%) | GS cohort (n = 111), N (%) | P-value |
|--------------------------------|--------------------------------|----------------------------|---------|
| Median age, y (range)          | 63 (23-89)                     | 62 (32-82)                 | 0.56    |
| Male sex                       | 431 (59.3)                     | 66 (59.5)                  | 0.99    |
| Median BMI, kg/m² (range)      | 22.7 (13-36.2)                 | 22.5 (15.6-32.5)           | 0.76    |
| ECOG performance status        |                                |                            |         |
| 0 or 1                         | 508 (69.9)                     | 89 (80.2)                  | 0.08    |
| 2                              | 187 (25.7)                     | 19 (17.1)                  |          |
| 3                              | 32 (4.4)                       | 3 (2.7)                    |          |
| Charlson comorbidity index     |                                |                            |         |
| 0                              | 196 (27.0)                     | 31 (27.9)                  | 0.63    |
| 1                              | 253 (34.8)                     | 39 (35.1)                  |          |
| 2                              | 172 (23.7)                     | 21 (18.9)                  |          |
| >2                             | 106 (14.6)                     | 20 (18.0)                  |          |
| Smoking                        |                                |                            |         |
| Never                          | 47 (65.5)                      | 56 (50.5)                  | 0.003   |
| Ever or active                 | 251 (34.5)                     | 55 (49.5)                  |          |
| Primary tumor site             |                                |                            |         |
| Head                           | 311 (42.8)                     | 32 (28.8)                  | 0.017   |
| Body                           | 124 (17.1)                     | 24 (21.6)                  |          |
| Tail                           | 139 (19.1)                     | 32 (28.8)                  |          |
| Overlapping                    | 153 (21.0)                     | 23 (20.7)                  |          |
| Presence of jaundice           |                                |                            |         |
| No                             | 482 (66.3)                     | 84 (75.7)                  | 0.06    |
| Yes                            | 245 (33.7)                     | 27 (24.3)                  |          |
| T-classification               |                                |                            |         |
| 1                              | 11 (1.5)                       | 2 (1.8)                    | 0.34    |
| 2                              | 68 (9.4)                       | 14 (12.6)                  |          |
| 3                              | 159 (21.9)                     | 30 (27.0)                  |          |
| 4                              | 489 (67.3)                     | 65 (58.6)                  |          |
| N-classification               |                                |                            |         |
| 0                              | 179 (24.6)                     | 19 (17.1)                  | 0.10    |
| 1                              | 548 (75.4)                     | 92 (82.9)                  |          |
| M-classification               |                                |                            |         |
| 0                              | 162 (22.3)                     | 22 (19.8)                  | 0.63    |
| 1                              | 565 (77.7)                     | 89 (80.2)                  |          |
| AJCC tumor stage               |                                |                            |         |
| III                            | 162 (22.3)                     | 22 (19.8)                  | 0.63    |
| IV                             | 565 (77.7)                     | 89 (80.2)                  |          |
| Median albumin, gm/dL (range)  | 3.80 (1.3-4.9)                 | 4.0 (2.7-4.9)              | 0.37    |
| Median NLR (range)             | 3.7 (0.7-43)                   | 3.3 (0.8-17)               | 0.10    |
| Site of metastases             |                                |                            |         |
| Liver                          | 381 (52.4)                     | 57 (51.4)                  | 0.84    |
| Peritoneum                     | 208 (28.6)                     | 31 (27.9)                  | 0.99    |
| Distant lymph nodes            | 133 (18.3)                     | 17 (15.3)                  | 0.51    |
| Lung                           | 85 (11.7)                      | 13 (11.7)                  | 0.99    |

(Continues)
treated with monotherapy and combination therapy, respectively (Figure 4A). In the intermediate prognostic group, the median OS were 8.0 (95% CI, 6.4-9.5 months) and 8.5 (95% CI, 7.5-9.5 months, P = .038) months for patients with monotherapy and combination therapy, respectively (Figure 4B). In the poor prognostic group, the median OS were 3.7 (95% CI, 3.2-4.1 months) and 5.7 (95% CI, 5.0-6.4 months, P = .001) months for patients treated with monotherapy and combination therapy, respectively (Figure 4C).

4 | DISCUSSION

This study provided validation of the previously developed GS model in predicting the survival outcome of APC patients

| Variable Category | Non-GS cohort, N (%) | GS cohort, N (%) | P-value |
|-------------------|---------------------|----------------|---------|
| ECOG PS 0 or 1    | 123 (6.5)           | 47 (3.6)       | 0.29    |
|                  |                     | 1 (100)        |         |
| ECOG PS 2        | 245 (50.2)          | 63 (8.7)       |         |
| ECOG PS 3        | 411 (83.8)          | 111 (100)      |         |
| Tumor stage III  | 165 (50.2)          | 63 (8.7)       |         |
| Tumor stage IV   | 455 (83.8)          | 111 (100)      |         |
| Albumin per g/dL | 0.60 (0.53-0.68)    | 0.82 (0.72-0.94) | .004  |
| NLR per ratio    | 1.04 (1.02-1.05)    | 1.02 (1.01-1.04) | .009  |

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance scale; NLR, neutrophil-to-lymphocyte ratio.

**Table 2**  Univariate and multivariate analysis of variables in the GS model for overall survival

**Table 1** (Continued)

| Characteristic | Univariate analysis | Multivariate analysis |
|----------------|---------------------|-----------------------|
|                | HR (95% CI)         | P-value               |
|                | Adjusted HR (95% CI)| P-value               |
| ECOG PS 0 or 1 | 1                   | 1                     |
|                | 2                   | .29                   |
|                | 3                   | .011                  |
| Tumor stage III | 1                  | 1                    |
| Tumor stage IV | 1.84 (1.52-2.22)   | <.001                 |
| Albumin per g/dL | 0.60 (0.53-0.68) | <.001                 |
| NLR per ratio  | 1.04 (1.02-1.05)   | <.001                 |

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance scale; NLR, neutrophil-to-lymphocyte ratio.

*Cox model analysis.

**Table 2**  Univariate and multivariate analysis of variables in the GS model for overall survival
receiving first-line palliative chemotherapy. In addition to survival outcome prediction, our data demonstrated the outstanding predictive ability of treatment response with the GS model. Our current study extended the clinical application of the GS model for survival prediction regardless of the chemotherapy regimen used for the treatment of patients with APC.

In line with the GS model,11 the current study helped identify performance status, tumor stage, albumin, and NLR as independent prognostic factors that predict survival outcome. Several prognostic models have been developed for survival prediction among APC patients receiving first-line palliative chemotherapy.14-25 Apart from patient factors (age, sex, performance status, weight loss), laboratory variables (albumin, white cell count, NLR, tumor markers) and tumor characteristics (stage, tumor size, metastatic organ, ascites) have all been reported to be independent prognosticators in different prognostic models.14-25 Although no consistent prognosticators were reported among different reports, all models showed that in addition to tumor factors, patient features also were relevant to prognosis in PC patients. Consequently, the GS model was constructed by the combination of tumor- and patient-related factors, which may be more effective at predicting survival outcome than either tumor or patient factors alone.

Table 4 summarizes and compares 13 published prognostic models for the prediction of the survival outcome of PC patients receiving palliative chemotherapy from a literature review.14-25 Only one of the models was designed prospectively 25; the others were retrospective studies. Of the 13 prognostic models, some were used for the prediction of survival outcome specifically for gemcitabine-based treatment,11,14,16,19,22,24,25 while the other models consisted a broad spectrum of chemotherapeutic regimens.15,17,18,20,21,23 The

| Treatment regimen | Prognostic group | N (%) | Median OS, months (95% CI) | HR (95% CI) | P-valuea |
|-------------------|------------------|-------|-----------------------------|-------------|----------|
| Overall (n = 727) | Good             | 186   | 13.4 (11.8-15.0)            | 1 (reference)| <.001    |
|                   | Intermediate     | 193   | 8.4 (7.7-9.0)               | 1.51 (1.22-1.88) | <.001    |
|                   | Poor             | 348   | 4.6 (4.1-5.1)               | 2.84 (2.34-3.45) | <.001    |
| Gemcitabine-based or miscellaneous agents combination (n = 394) | Good             | 106   | 12.8 (10.4-15.2)            | 1 (reference) | <.001    |
|                   | Intermediate     | 119   | 8.7 (7.7-9.7)               | 1.39 (1.06-1.83) | .019     |
|                   | Poor             | 143   | 5.8 (5.0-6.6)               | 2.42 (1.85-3.16) | <.001    |
| Gemcitabine alone (n = 264) | Good             | 53    | 13.6 (11.7-15.5)            | 1 (reference) | <.001    |
|                   | Intermediate     | 52    | 7.7 (6.3-9.2)               | 1.70 (1.13-2.54) | .011     |
|                   | Poor             | 159   | 3.7 (3.1-4.2)               | 3.00 (2.13-4.24) | <.001    |
| 5-FU or S-1 alone (n = 69) | Good             | 20    | 15.2 (9.0-21.4)             | 1 (reference) | <.001    |
|                   | Intermediate     | 10    | 8.8 (2.8-14.3)              | 1.74 (0.73-4.10) | .21      |
|                   | Poor             | 39    | 3.7 (2.7-4.7)               | 2.99 (1.63-5.50) | <.001    |

Abbreviations: 5-FU, 5-fluouracil; CI, confidence interval; HR, hazard ratio; OS, overall survival.

*Cox model analysis.
performance reflected by C-index ranged from 0.66 to 0.80 among these prognostic models. Only five models were validated by application to a different cohort. Because the GS model is easily applied and had good performance in term of C-index value in the original and the current cohort, we believe this model to be widely applicable by clinicians to predict survival outcome in APC patients receiving first-line palliative chemotherapy.

Due to the increased toxicity profiles in combination chemotherapy, meta-analyses have indicated that such treatments might provide survival benefit only in APC patients with a good performance status and might be harmful in these with a poor performance status. The gemcitabine and S-1 Trial (GEST) study was a phase III trial conducted to compare the clinical efficacy of S-1 monotherapy, gemcitabine monotherapy, and S-1 and gemcitabine combined therapy as first-line chemotherapy for APC. The study

![FIGURE 3](image)

**FIGURE 3** Best tumor response to chemotherapy, stratified according to the GS model. PD, progressive disease; PR, partial response; SD, stable disease

![FIGURE 4](image)

**FIGURE 4** In-group survival differences of patients with advanced pancreatic cancer administered monotherapy or combination therapy. A, Patients in the good prognosis group. B, Patients in the intermediate prognosis group. C, Patients in the poor prognosis group.
| Study               | Year | Country         | Number of patients | Characteristics | Chemotherapy regimen | Validation | Prognostic factors                                                                 | C-index |
|--------------------|------|-----------------|--------------------|-----------------|----------------------|------------|-------------------------------------------------------------------------------------|---------|
| Yi, et al          | 2011 | Korea           | 298                | Retrospective   | Gemcitabine-based    | No         | Liver metastasis, ascites or carcinomatosis, CRP, albumin                            | NR      |
| Inal, et al        | 2012 | Turkey          | 343                | Retrospective   | Gemcitabine or      | No         | Stage, weight loss, CEA                                                            | NR      |
|                    |      |                 |                    |                 | Gemcitabine plus cisplatin |            |                                                                                     |         |
| Hamada, et al      | 2014 | Japan           | 531                | Retrospective   | Gemcitabine-based    | No         | Age, sex, PS, tumor size, regional lymph node metastasis, distant metastasis       | 0.686   |
| Xue, et al         | 2015 | China           | 118                | Retrospective   | Gemcitabine- or S-1-based | No         | PS, CA19-9, CRP                                                                    | NR      |
| Kurihara, et al    | 2015 | Japan           | 182                | Retrospective   | Gemcitabine plus S-1 | No         | PS, Stage, ANC                                                                     | NR      |
| Kou, et al         | 2016 | Japan           | 306                | Retrospective   | Gemcitabine monotherapy, S-1 monotherapy, gemcitabine plus S-1, and gemcitabine plus erlotinib | No         | PS, distant metastatic disease, initially unresectable disease, CEA, CA 19-9, Neutrophils and lymphocytes | 0.658   |
| Xue, et al         | 2017 | China           | 153 (training set) | Retrospective   | All                  | Yes        | Lymphocytes and monocytes                                                          | NR      |
|                    |      | Japan           | 252 (validation set)|                 |                      |            |                                                                                     |         |
| Deng, et al        | 2017 | China           | 1017 (training set)| Prospective, randomly assign | Gemcitabine-based | Yes        | Age, tumor stage, tumor size, ALT, albumin, CA 19-9, hepatitis B virus infection status | 0.720 (training set) 0.696 (validation set) |
|                    |      |                 | 509 (validation set)|                 |                      |            |                                                                                     |         |
| Ventriglia, et al  | 2018 | Italy           | 70                 | Retrospective   | Nab-paclitaxel plus gemcitabine | No         | PS, liver metastasis, NLR                                                          | NR      |
| Hang, et al        | 2018 | China           | 133 (training cohort) | Retrospective from three clinical trials | NR             | Yes        | PS, liver metastasis, CA 19-9, ANC, albumin                                          | 0.699 (training cohort) 0.658 (validation cohort) |
|                    |      |                 | 273 (validation cohort)|                 |                      |            |                                                                                     |         |
| Wang, et al        | 2018 | China           | 94                 | Retrospective   | Gemcitabine or 5-FU-based | No         | LDH, CA19-9, CRP, albumin                                                          | NR      |
| Zhang, et al       | 2019 | China           | 197 (training cohort) | Retrospective | NR | Yes | Platelet, neutrophil, lymphocyte counts                                     | NR      |
|                    |      |                 | 222 (validation cohort)|                 |                      |            |                                                                                     |         |
| Chang, et al       | 2019 | Taiwan          | 111                | Retrospective   | Gemcitabine + S-1   | Yes        | PS, stage III or IV, neutrophil, lymphocyte, albumin                              | 0.80    |
| Current study      |      | Taiwan          | 727                | Retrospective   | All regimen         | ...        | ...                                                                                  | 0.73    |

Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count; CA19-9, carbohydrate Antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; NR, not recorded; PS, performance status.
results revealed nonsignificant differences in survival between the three treatment groups, especially for patients with a performance status of 0. However, in patients with a performance status of 1, GS combination therapy provided a longer survival time than that of monotherapy (median OS 9.6 months for GS, 6.2 months for gemcitabine, and 6.3 months for S-1). In line with those of the GEST, our results showed similar survival outcomes for patients in the good prognostic group regardless of treatment with monotherapy or combination therapy; in contrast, patients in the intermediate or poor prognostic groups receiving monotherapy had distinctly worse survival than those receiving combination therapies. Due to conflicting results regarding the impact of combination therapy or monotherapy on survival in patients with poor performance status, a well-designed prospective study may help to elucidate the effect of these therapies on survival outcome in APC patients.

The R-square value for the GS model in our patient cohort was 0.11, suggesting an unsatisfied linear correlation of the GS prognostic score and OS. However, a significant in-groups survival difference supported that the prognostic groups stratification according to the GS model was accurate to provide survival discrimination. The results of the current study supported the use of the GS model for guidance in treatment planning for APC patients. With the intent to prolong survival outcome, patients in the intermediate or poor prognostic groups in the GS model should be encouraged to receive combination therapy rather than monotherapy. Nonetheless, patients should also be informed that the gain of survival benefit is potentially accompanied by additional toxicity from the combination therapies.

The strength of this study rests in its having the largest cohort among currently published prognostic studies used for the validation of a robust prognostic model. Despite some differences in clinical parameters between the non-GS and GS cohorts, the results of the current study supported the generalization of the GS model as an accurate prognostic tool in patients with APC. Because all the parameters of the GS model are easily accessible, objective, and available upon initiation of systemic chemotherapy, we believe that it could be widely applied as a simple prognostic tool for APC patients receiving all types of first-line chemotherapy regimens. The current study not only includes large patient samples, most importantly, but also validates the model performance by allocated patients according to different chemotherapy regimens. However, the current study had several limitations. First, our study is susceptible to selection bias due to its retrospective approach. Second, a long initial “plateau” for patients in the good prognostic group in the Kaplan-Meier plots might raise the concerns of a survival bias. Malnutrition and infection are the main leading causes of death in patients with pancreatic cancer. Patients in good prognostic group possess better general condition in terms of good performance and higher albumin level against these threats and may tolerate anticancer treatment better. This could be the cause of a long initial “plateau” for patients in the good prognostic group in the Kaplan-Meier plots. A prospective study is needed to eliminate questions about the selection and survival bias in this study. Third, since the choice of chemotherapy regimen and dosing is individualized by physician and patient preferences, personalized treatment choice may potentially confound patient outcome, contributing to selection bias in the present study. Finally, due to the lack of insurance support in Taiwan, less than 1% of our patients received FOLFIRINOX or gemcitabine plus nab-paclitaxel, which are the standard first-line chemotherapy regimens for pancreatic cancer in Western countries. Thus, the applicability of the GS model as a prognostic model in Western patients with APC remains unknown.

5 | CONCLUSION

The results of our study validated the GS model’s competence in predicting survival outcome in a large cohort of patients with unresectable or metastatic PC. Moreover, the results supported the clinical application of the GS model in the first-line treatment of APC with gemcitabine-based regimens. In addition, our results suggested that the GS model may be used to predict tumor response and provide guidance when choosing between monotherapy or combination chemotherapy among patients in different prognostic groups in the GS model.

ACKNOWLEDGMENTS

We thank Ms Vengi Ho and the members of the Cancer Center, Chang Gung Memorial Hospital for their assistance with data collection.

CONFLICT OF INTEREST

The authors declare that no competing interests exist.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Chia-Yen Hung https://orcid.org/0000-0002-6691-0192
Wen-Chi Chou https://orcid.org/0000-0002-0361-4548
REFERENCES

1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73-85.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
3. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049.
4. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
5. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
6. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703.
7. Jin SF, Fan ZK, Pan L, Jin LM. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials. Hepatobiliary Pancreat Dis Int. 2017;16(3):236-244.
8. Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14:471.
9. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
10. Xie DR, Yang Q, Chen DL, et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol. 2010;40(5):432-441.
11. Chang C-F, Huang P-W, Chen J-S, et al. Prognostic factors for advanced pancreatic cancer treated with Gemcitabine plus S-1: retrospective analysis and development of a prognostic model. Cancers (Basel). 2019;11(1):57.
12. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640-1648.
13. Eisenhauer E, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
14. Zhang KE, Hua Y-Q, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019;17(1):30.
15. Yi JH, Lee J, Park SH, et al. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology. 2011;80(3-4):175-180.
16. Xue P, Zhu L, Wan Z, et al. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol. 2015;141(9):1653-1660.
17. Xue P, Hang J, Huang W, et al. Validation of lymphocyte-to-monocyte ratio as a prognostic factor in advanced pancreatic cancer: an East Asian cohort study of 2 countries. Pancreas. 2017;46(8):1011-1017.
18. Wang YI, Xiao X, Wang T, et al. A survival model in locally advanced and metastatic pancreatic ductal adenocarcinoma. J Cancer. 2018;9(7):1301-1307.
19. Ventriglia J, Petrolli A, Huerta Alváro M, et al. Neutrophil to lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: a propensity score analysis. Gastroenterol Res Pract. 2018;2018:2373868.
20. Kurihara T, Kogo M, Ishii M, et al. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1. Hepatogastroenterology. 2015;62(138):478-484.
21. Kou T, Kanai M, Yamamoto M, et al. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Int J Clin Oncol. 2016;21(1):118-125.
22. Inal A, Kos FT, Algin E, et al. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. J BUON. 2012;17(1):102-105.
23. Hang J, Wu L, Zhu L, et al. Prediction of overall survival for metastatic pancreatic cancer: development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer Med. 2018;7(7):2974-2984.
24. Hamada T, Nakai Y, Yasunaga H, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110(8):1943-1949.
25. Deng Q-L, Dong S, Wang L, et al. Development and validation of a nomogram for predicting survival in patients with advanced pancreatic ductal adenocarcinoma. Sci Rep. 2017;7(1):11524.
26. Okusaka T, Miyakawa H, Fujii H, et al. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol. 2017;143(6):1053-1059.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Huang P-W, Chang C-F, Hung C-Y, et al. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Med. 2019;8:5554–5563. https://doi.org/10.1002/cam4.2483